Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eli Lilly Japan and Sumitomo Dainippon Pharma have signed a sales collaboration agreement for a once-weekly GLP-1 receptor agonist, Trulicity Subcutaneous Injection 0.75mg Ateos (Trulicity).
Subscribe to our email newsletter
For Trulicity, Eli Lilly Japan has secured a manufacturing/marketing license as a drug indicated to treat people with type 2 diabetes in Japan.
Trulicity is a once-weekly glucagon-like peptide-1 receptor agonist that acts on the GLP-1 receptor in the way similar to that of the GLP-1, a gastrointestinal hormone.
Under the deal, Eli Lilly Japan retains a manufacturing/marketing license for Trulicity, while Sumitomo Dainippon Pharma will be responsible for overseeing the sales/distribution of the drug.
Both the firms will conduct activities to provide healthcare professionals with information regarding Trulicity.
Sumitomo Dainippon Pharma Sales & Marketing senior executive officer and executive director Susumu Nakajima said: "Our company positions the diabetes area as one of the important areas in domestic sales and is selling multiple type 2 diabetes drugs with different action mechanisms.
"With the sales collaboration agreement signed this time, a once-weekly GLP-1 receptor agonist joined our product lineup that is expected to make a further contribution to the treatment of type 2 diabetes by expanding treatment options for patients."
By building a close cooperative relationship through the sales collaboration of Trulicity, the two firms plan to make a further contribution to the treatment of type 2 diabetes.